NetProspex, New Entrant in the $20bn Sales Desktop Market for Trading Executive Contacts, Secures Series B Funding

Waltham, MA (PRWEB) May 23, 2008

NetProspex Inc., a recent entrant in the market to create the world's most accurate and extensive database of sales contacts, announced that it has secured Series B funding from angel investors. The company will use the funding to further develop its proprietary tools to bring accurate sales contact information to the sales desktop.

NetProspex helps customers maximize their ROI by providing them with higher quality, and more accurate, sales leads. Customers pool their contacts with NetProspex's database in exchange for new contacts. A range of proprietary technologies is used to ensure that the customer-supplied data is validated up front and that the quality of the database is maintained over time. The result is a unique resource of executive contacts that reaches far deeper than alternatives.

"Our business has been growing at a brisk pace and as a result we were able to complete our funding round in less than 2 months. This continued vote of confidence from our investors is truly gratifying," says Gary Halliwell, CEO and founder of NetProspex. "Our work in raising the bar on data quality for sales contacts and the success of our contact trading platform has laid the groundwork for continued growth of the company."

NetProspex angel investors include business media publishing veterans Rikki Tahta, Simon Murdoch, Roland Beaulieu and Gary Mueller.

About NetProspex

Founded in 2006, NetProspex understands that effective sales efforts require the most in-depth and accurate prospect data. The company's core product line overlays user-contributed and commercial sales lead data with multiple layers of quality control to produce an entirely unique and highly effective sales and marketing contact database. With over 2.5 million accurate business contacts across 350,000 companies, NetProspex is a major new source of contacts, including difficult-to-find mid-management decision makers across North American businesses. For more information or a free trial, visit http://www.netprospex.com.

###

Patheon Announces Appointment of Michael E. Lytton as Executive Vice President, Corporate Developement and Strategy, and General Counsel

Toronto (PRWEB) May 11, 2011

Patheon (TSX: PTI) announced today the appointment of Michael E. Lytton as Patheons Executive Vice President, Corporate Development and Strategy and General Counsel, effective immediately. Mr. Lytton was most recently with Biogen Idec, Inc., where he held the position of Executive Vice President, Corporate and Business Development reporting to Jim Mullen, previously Chief Executive Officer of Biogen Idec and now Patheons Chief Executive Officer.

In commenting on the appointment, Mr. Mullen said, I am so pleased that Michael has agreed to join us. He is an accomplished leader, strategist and negotiator who will bring a deep and broad understanding of the industry and proven skills to help Patheon reach its full potential. I expect that Michael will assist us in building strategic alliances with our pharmaceutical and biotechnology customers as well as emerging companies and their investors, and that he will enable us to add a range of proprietary capabilities and technologies to better serve our customers.

Mr. Lyttons 28-year career includes extensive experience in the pharmaceutical and biotech industry. Most recently, Mr. Lytton supported Biogen Idecs growth by leading its corporate development team that refined and executed its corporate partnership strategy, including the in-licensing of several late-stage molecules. Prior to joining Biogen Idec, Mr. Lytton was a General Partner with Oxford Bioscience Partners, a venture capital firm investing in therapeutic, diagnostic, and life science tool companies. Prior to Oxford, Mr. Lytton practiced law for 17 years and specialized in representing biomedical companies; he is a past Partner and member of the Executive Committee of the law firm Edwards Angell Palmer & Dodge and previously was a Partner of the law firm Wilmer Hale.

Mr. Lytton is currently Chairman of the Board of Santhera Pharmaceuticals AG and he has also served on various boards of many other academic, non-profit and private and public for-profit companies throughout his career.

Mr. Lytton holds an undergraduate degree from Princeton University, a Master of Science degree in Epidemiology from the London School of Hygiene and Tropical Medicine at the University of London, U.K. where he was a Fulbright Scholar, and a Juris Doctor from Harvard Law School.

ABOUT PATHEON

Patheon is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. It provides the highest quality products and services to approximately 300 of the worlds leading pharmaceutical and biotechnology companies. Patheons services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semisolid and liquid forms. The company uses many innovative technologies including singleuse disposables, liquidfilled hard capsules and a variety of modified release technologies. Its comprehensive range of fully integrated Pharmaceutical Development Services includes preformulation, formulation, analytical development, clinical manufacturing, scaleup and commercialization. Patheon can take customers direct to clinic with global clinical packaging and distribution services and Patheons Quick to Clinic programs can accelerate early phase development projects to clinical trials while minimizing the consumption of valuable API. Its integrated development and manufacturing network of 10 facilities, eight development centers and one clinical trial packaging facility, across North America and Europe, ensures that customer products can be launched ontime and with confidence anywhere in the world.

Patheon Contact:

Wendy Wilson

Investor Relations and Corporate Communications

Tel: (919) 226-3313

Email: wendy.wilson(at)patheon(dot)com

###